Navigation Links
UMMS researchers develop new technology to screen and analyze genetic mutations

WORCESTER, Mass. A single change to even one of the thousands of DNA codes that make up each gene in the human genome can result in severe diseases such as cancer, cystic fibrosis, muscular dystrophy or Huntington's Disease. A similarly minor change in the DNA of a virus or bacteria can give rise to drug resistant strains that are difficult for physicians to treat with standard drug therapies. For these reasons, scientists have long sought ways to study the effects genetic mutations can have on an organism but have been hampered in these efforts by an inability to easily and efficiently produce and analyze the thousands of potential changes possible in even one small gene.

A new study by scientists at the University of Massachusetts Medical School, published in Early Edition of the Proceedings of the National Academy of Sciences online on April 4, describes a novel technique to produce all potential individual mutations and using deep sequencing technology simultaneously analyze each change's impact on the cell.

"In nature, genetic mutations actually occur infrequently and at random," said Daniel N. A. Bolon, PhD, assistant professor of biochemistry & molecular pharmacology and lead author of the PNAS study. "But these small changes have profound consequences on an organism's ability to survive. We've developed an approach that allows us to generate all the possible individual changes and, at the same time in the same test tube, study the impact of each change."

Using sequencing technology inspired by the human genome project, Bolon and colleagues have developed a method called EMPIRIC to analyze hundreds of different mutations in a single test tube. Ordinarily used to read a DNA sequence over an entire genome, Bolon utilizes the ability of this band-aid-sized sequencing chip to accurately count and record the abundance of hundreds of distinct cells in a test tube that differ by individual mutations. At its most simple, mutations that are beneficial will grow rapidly and increase in abundance, while mutations that are harmful will decrease in relative abundance.

Examining a nine amino acid region essential for the survival of baker's yeast, Bolon and colleagues were able to analyze 180 different amino acid substitutions representing more than 500 different DNA mutations for this small genetic region. "The key breakthrough was the realization that we could analyze a multitude of mutations at the same time, in the same test tube," said Bolon. "What would have taken years of work and thousands of test tubes can be done in a matter of days in one test tube."

Their findings were consistent with current models of molecular evolution in which a large number of mutations are harmful, but the great majority of mutations have little to no effect on the cell's function. With this approach, scientists can gain new insights into a host of biological questions including how environmental pressures influence evolutionary processes on a genetic level, what mutations are likely to cause genetic disease and how to screen viruses for mutations that might lead to drug resistance.

Viruses, because of their relatively limited genetic code, represent an ideal target for this novel approach. For example, with this new technique, an entire viral genome can be systematically screened for its likelihood to develop resistance to drug therapies. By inserting the drug into the test tube with all the possible mutations, scientists can systematically identify all individual viral mutations that increase drug resistance. Currently, resistance screening techniques are less effective because they rely on testing random mutations, leaving the possibility that an untested mutation might lead to resistance. Systematically identifying resistant mutations may provide new routes to the development of therapeutics and vaccines that minimize resistance.

"One of the truly exciting aspects about this approach is that it's so general," said Bolon. "While our experiments were carried out on yeast cells, it can be applied to any fast growing cell that can be genetically manipulated such as cancer cells, viruses or bacteria."


Contact: Jim Fessenden
University of Massachusetts Medical School

Related biology news :

1. Livermore researchers develop battery-less chemical detector
2. Researchers ID microbe responsible for methane from landfills
3. Researchers identify new role for cilia protein in mitosis
4. Researchers link herpes to Alzheimers disease
5. Researchers say children need horticultural interventions
6. Berkeley Lab researchers make first perovskite-based superlens for the infrared
7. Kentucky researchers find a key to plant disease resistance
8. Researchers unlock new secret to how smells are detected
9. RIT researchers help map tsunami and earthquake damage in Japan
10. Dont shuffle on slippery surfaces, Clemson University, Charleston researchers say
11. U of M researchers close in on technology for making renewable petroleum
Post Your Comments:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology: